Research ArticleCancer

A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management

See allHide authors and affiliations

Science Translational Medicine  07 Mar 2018:
Vol. 10, Issue 431, eaan8840
DOI: 10.1126/scitranslmed.aan8840

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Tracing tumor treatment response

Tyrosine kinase inhibitors (TKIs) are a therapy for patients with non–small cell lung cancer (NSCLC) who have activating mutations in epidermal growth factor receptor (EGFR). To noninvasively detect tumor mutation status, Sun et al. designed a radiolabeled tracer for use with positron emission tomography and computed tomography imaging methods. The tracer identified tumors with activating mutant EGFR in rodent models of NSCLC and in patients with NSCLC. Patients with mutant EGFR had longer progression-free survival and responded to TKI therapy at a higher rate compared to patients with wild-type EGFR. This tracer could help identify patients with EGFR-TKI sensitivity and could be useful for monitoring response to treatment.